Xenon Pharmaceuticals Inc.
| Public | |
| Traded as | NASDAQ: XENE |
| ISIN | 🆔 |
| Founded 📆 | 5 November 1996 in Burnaby, British Columbia, Canada |
| Founder 👔 | Simon Pimstone, Johannes Kastelein, Michael Hayden |
| Headquarters 🏙️ | , Burnaby, British Columbia , Canada |
Area served 🗺️ | |
| Products 📟 | |
| Members | |
Number of employees | |
| 🌐 Website | [Lua error in Module:WikidataIB at line 665: attempt to index field 'wikibase' (a nil value). ] |
| 📇 Address | |
| 📞 telephone | |
Xenon Pharmaceuticals is a biopharmaceutical company focused on improving the lives of people with neurological and psychiatric disorders. As of December 31st, 2023, Xenon Pharmaceuticals has 259 employees,[1] a reported increase of 46 employees since the previous year.
Founded in 1996 by Simon Pimstone, Johannes Kastelein, and Michael Hayden, Xenon Pharmaceuticals is currently headquartered in Burnaby, Canada, with operations in Vancouver, Canada and Boston, Massachusetts, USA.[2]
Since then, the company has been advancing clinical trials for several drugs in its pipeline, such as XEN1101 for focal onset seizures and generalized tonic-clonic seizures (both currently in phase III clinical trials), XEN1101 for MDD, also with an investigator-led collaboration study with Mount Sinai, both of which are awaiting approval to enter Phase III clinical trials. There are also phase II clinical trials underway with Neurocrine Biosciences for NBI-921352 (formerly XEN901) for treating patients with SCN8A and EEIE.[3]
It has also discontinued clinical trials for drugs either due to acquisition by another company or for other reasons, such as Funapide (formerly TV-45070 and XEN402), which has no current plans for entering phase III clinical trials, according to Pacira Biosciences' pipeline after acquiring Flexion Therapeutics in Oct. 2021.[4]
References
External links
This article "Xenon Pharmaceuticals" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Xenon Pharmaceuticals. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
